Dioxaphetyl butyrate

Dioxaphetyl butyrate
Clinical data
Other names	Amidalgon, Spasmoxal
Routes of; administration	Oral, Other ROA Unknown
ATC code	none;
Legal status
Legal status	AU: S9 (Prohibited substance); CA: Schedule I; DE: Anlage I (Authorized scientific use only); US: Schedule I;
Identifiers
	IUPAC name Ethyl 4-morpholin-4-yl-2,2-di(phenyl)butanoate;
CAS Number	467-86-7 ;
PubChem CID	48194;
ChemSpider	43838 ;
UNII	G751H98FY4;
CompTox Dashboard (EPA)	DTXSID20196914 ;
ECHA InfoCard	100.006.731
Chemical and physical data
Formula	C22H27NO3
Molar mass	353.45 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)C(CCN1CCOCC1)(c1ccccc1)c1ccccc1;
	InChI InChI=1S/C22H27NO3/c1-2-26-21(24)22(19-9-5-3-6-10-19,20-11-7-4-8-12-20)13-14-23-15-17-25-18-16-23/h3-12H,2,13-18H2,1H3 ; Key:LQGIXNQCOXNCRP-UHFFFAOYSA-N ;
	(what is this?) (verify)

Dioxaphetyl butyrate (INN; trade names Amidalgon, Spasmoxal) is an opioid analgesic which is a diphenylacetic acid derivative, related to other open-chain opioid drugs such as dextropropoxyphene, levacetylmethadol (LAAM), lefetamine and dimenoxadol.

It produces similar effects to other opioids, including dependence, euphoria, analgesia, sedation, constipation, dizziness and nausea.

In the United States it is a Schedule I Narcotic controlled substance with an ACSCN of 9621 and a 2013 annual aggregrate manufacturing quota of zero.

References

This analgesic-related article is a stub. You can help Wikipedia by expanding it.